Best Healthcare Companies in Wallonia, Belgium
The 68 best Healthcare companies in Wallonia, Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Eyed Pharma.
Ranked: Best Healthcare companies in Wallonia
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 2B Clinic Standalone general clinic | — | — | 1 | — | PHPGoogle MapsTypekit+7 | Top 50M | — | — |
| 2 | Accessia Provider of clean-rooms, labs and office to bio-pharmaceutical sector | — | — | 4 | — | — | — | — | — |
| 3 | AGD Invest Retailer of cannabis flowers, oils, cigarettes, and other products | — | — | 1 | — | Wix eCommerceCart FunctionalityWix+13 | Top 50M | — | — |
| 4 | Allyfe Developer of a SaaS platform streamlining regulatory document management for biopharma | — | — | — | Jean-François Lecocq Co Founder & Head of Quality Assurance @ Allyfe | — | — | — | — |
| 5 | ANMI CDMO focused on synthesis of APIs | — | — | 20 | — | — | — | 20 patents Ga‑68 radiopharmaceutical labeling kits using sugar‑based metal inhibitors | — |
| 6 | Ars Statistica Provider of clinical trial consulting services for biopharma sector | — | — | — | — | — | — | — | — |
| 7 | Artialis Provider of preclinical, clinical, and biomarker-based solutions for product development in musculoskeletal… | — | — | 15 15 → 13 (-13%) · sector median +32% | Yves Henrotin Founder | — | — | — | — |
| 8 | Aseptic Technologies Manufacturer of aseptic filling equipment and ready-to-use devices for the pharmaceutical and biotech… | — | — | 10 | Patrick Baleriaux CEO & MD | BootstrapGSAPStimulus+10 | Top 50M | 29 patents Sterile pharmaceutical packaging, container closures, lyophilized product processing, and medical needle design. | — |
Top 12 Healthcare companies in Wallonia
#1
Public · Charleroi, Wallonia · founded 2020 · 5 employees$10.6Mraised▾
CDMO focused on developing of gene therapies to reverse the aging processes
- Mar 2026Grant (prize money)$4.7M
- Oct 2024Grant (prize money)$1.3M
- Apr 2024Post IPO$901.1K
- Mar 2022Grant (prize money)$3.7M
#2
Series B · Mont Saint Guibert, Wallonia · founded 2013 · 16 employees$16.5Mraised▾
Provider of data modeling and patient insights for clinical trial optimization. It offers solutions to predict patient behavior and drug responses, aiming to improve the predictability of clinical trials. The company focuses on reducing data variability caused by placebo response and patient heterogeneity to demonstrate treatment efficacy. It also provides tools to predict patient nonadherence and dropout risk, helping to strengthen patient engagement and improve study power for more informed clinical development decisions.
- Apr 2024Series B$16.5M
#3
Series B · Liege, Wallonia · founded 2013 · 64 employees$59.9Mraised▾
Manufacturer of ophthalmology drugs
- Jan 2022Series B$51M
- May 2019Series A$8.9M
- May 2019Conventional Debt$22.3M
#4
Series B · Gembloux, Wallonia · founded 1998 · 25 employees$11.8Mraised▾
Provider of endovascular treatment services
#5
Acquired · Charleroi, Wallonia · founded 2011 · 329 employees$17.4Mraised▾
MaSTherCell (Manufacturing Synergies for Therapeutic Cells) is a Belgian Contract Development and Manufacturing Organisation, offering its services for the development of cell therapy products. Company's services include process and assay development, GMP manufacturing and quality control services of cell therapy products. The company's services can be availed right from Phase - I to commercialization of the product. Their facilities are authorized by Belgian Drug Agency (AFMPS). The company claims that their quality control services are performed in accordance with European and US pharmacopeia, FDA and EMA. MaSTherCell was acquired by Orgenesis (a company offering cellular therapy and regenerative medicines for the treatment of Type 1 Diabetes) in March 2015. In August 2016, the company was selected by Adaptimmune as a supplier of cell therapy products for use in Adaptimmune’s clinical trials.
- Jun 2018Series A$11.8M
- 2011Seed$5.6M
#6
Funding Raised · Liege, Wallonia · founded 2016 · 28 employees$1.5Mraised▾
Provider of clinical trials support & software services for medical devices manufacturers
- Jan 2023Grant (prize money)$217.4K
- Oct 2020Grant (prize money)$766.3K
- Oct 2017Grant (prize money)$556.3K
#7
Funding Raised · Ottignies Louvain la Neuve, Wallonia · founded 2013 · 1 employees$1.2Mraised▾
Manufacturer of drug development and drug research services to biopharma
- Feb 2018Grant (prize money)$460.7K
- Jan 2018Grant (prize money)$460.7K
- Jan 2016Grant (prize money)$235.5K
#8
Series A · Liege, Wallonia · founded 2017 · 6 employees$872Kraised▾
CDMO focused on manufacturing of cell therapy products
- Jan 2018Series A$872K
- Jan 2018Conventional Debt$367K
#9
Acquired · Charleroi, Wallonia · founded 2014 · 22 employees$1Mraised▾
ImmunXperts is a CRO engaged in the development of bioassays which involve the human immune system for drug development (biopharmaceutical, biosimilar and vaccines) applications. Their applications include immunogenicity of biotherapeutics (in vitro, in silico, in vivo and clinical services and regulatory support), and immuno-oncology (MLR Assays, Antigen-specific T cell activation and macrophage polarisation assays) and cell therapy (custom assays) development. They also offer services for the development of functional potency assays in the field of stem cell therapy. The company has received 1.6 million euro grant, along with other institutes and companies, to identify innovative drug candidates and biomarkers for immunotherapy of various types of cancer.
- Oct 2016Grant (prize money)—
- Dec 2014Seed$1M
#10
Funding Raised · Mont Saint Guibert, Wallonia · founded 2018 · 5 employees$308.7Kraised▾
Developer of cancer therapies designed to discover first-in-class small molecule therapeutics for unmet needs in oncology. The company's therapies are dedicated to launching a drug development program aimed at identifying potential new candidates for cancer target inhibitors, enabling cancer patients to access therapies for various types of cancer.
- Mar 2021Grant (prize money)$308.7K
#11
Funding Raised · Eghezee, Wallonia · founded 1996 · 20 employees—raised▾
Vésale Pharma is a Belgian pharmaceutical company that focuses on developing innovative solutions for everyone's well-being. They offer a range of products in various therapeutic fields, including dermatology and gastroenterology.
#12
Acquired · Seraing, Wallonia · founded 1985 · 426 employees—raised▾
Eurogentec S.A., is a leading global supplier of innovative reagents, kits, specialty products and custom services. It has three inter-related business units (BU). Life Science Research BU is specialized in innovative solutions in Genomics and Proteomics, through which it supplies a wide range of reagents, kits and consumables for Life Science applications such as Custom Oligonucleotides, high performance PCR/qPCR Kits & Reagents, catalogue dyes, peptides & antibodies. It also offers custom synthesis of petides and antibodies. The Diagnostic Services BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases. The GMP BioManufacturing BU is a US FDA inspected full-service Contract Manufacturing Organization (CMO). It offers expertise in technology transfer, process development, scale-up and cGMP manufacturing of proteins, protein conjugates, plasmid DNA and bacterial vaccines for pre-clinical, clinical and commercial uses. They claim to be experts in microbial cell lines (E.coli, P. pastoris etc.,) and also to have developed over 100 different GMP biopharmaceuticals since 1994. In 2009, Eurogentec acquired AnaSpec, a provid
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Healthcare coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.